Novo Nordisk Acquires Cardior Pharmaceuticals for $1.112B in Effort to Bolster Cardiovascular Disease Pipeline

Deal includes the novel treatment CDR132L, which is currently in Phase II clinical trials for heart failure.

Source link
#Novo #Nordisk #Acquires #Cardior #Pharmaceuticals #1.112B #Effort #Bolster #Cardiovascular #Disease #Pipeline